Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(20 sites)
United States
University of Alabama at Birmingham, Children's of Alabama, Birmingham, Alabama Children's Hospital of Los Angeles, Los Angeles, California Rady Children's Hospital, San Diego, California University of California, San Francisco, San Francisco, California Children's National Hospital, Washington D.C., District of Columbia University of Florida, Gainesville, Florida Riley Children's Hospital, Indianapolis, Indiana Johns Hopkins University, Baltimore, Maryland Dana Farber Cancer Institute, Boston, Massachusetts Washington University St. Louis, St Louis, Missouri Hackensack Meridian Children's Health at Joseph M. Sanzari Children's Hospital, Hackensack, New Jersey Duke Children's Hospital & Health Center, Durham, North Carolina Children's Hospital of Philadelphia, Philadelphia, Pennsylvania University of Utah, Salt Lake City, Utah Australia
Sydney Children's Hospital, Sydney, New South Wales The Children's Hospital at Westmead, Westmead, New South Wales Queensland Children's Hospital, South Brisbane, Queensland Women's and Children's Hospital, North Adelaide, South Australia Royal Children's Hospital, Parkville, Victoria Perth Children's' Hospital, Perth, Western Australia